The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018
Carolien C. H. M. Maas, David van Klaveren, Geneviève I. C. G. Ector, Eduardus F. M. Posthuma, Otto Visser, Peter E. Westerweel, Jeroen J. W. M. Janssen, Nicole M. A. Blijlevens, Avinash G. Dinmohamed
Abstract
Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989-2018. As of the early 2010s, the life expectancy of patients with CML who survived several years after diagnosis came narrowly close to the general population's life expectancy, regardless of age. This finding can essentially be ascribed to the introduction and broader application of tyrosine kinase inhibitors (TKIs) and provide optimism to patients with CML who can look forward to a near-normal life expectancy in a modern TKI era.